Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 6/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | VNN1 | O95497 | 4/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583051 | 0.86 | IDH1 (0.44) | HDAC1HDAC8HDAC6IDH1 | |
| SCHEMBL4580943 | 0.85 | HDAC1 (0.43) | HDAC1HDAC8HDAC6IDH1VNN1 | |
| SCHEMBL4581890 | 0.84 | IDH1 (0.54) | IDH1HRH4 | |
| SCHEMBL4580658 | 0.83 | IDH1 (0.44) | HDAC1HDAC8HDAC6IDH1HRH4 | |
| SCHEMBL4579971 | 0.82 | KDM4E (0.42) | HDAC1HDAC8HDAC6IDH1VNN1 | |
| SCHEMBL4580232 | 0.81 | IDH1 (0.46) | IDH1HRH4 | |
| SCHEMBL4579658 | 0.81 | IDH1 (0.46) | HDAC1HDAC8HDAC6IDH1HRH4 | |
| SCHEMBL4582884 | 0.80 | HRH4 (0.43) | HDAC1HDAC8HDAC6IDH1HRH4 | |
| SCHEMBL4581479 | 0.80 | IDH1 (0.44) | HDAC1HDAC8HDAC6IDH1HRH4 | |
| SCHEMBL4580579 | 0.80 | ACHE (0.47) | IDH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | HDAC1 481/4885HDAC8 1903/4885HDAC6 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.